TDCANN provides Endocannabinoid System educational seminars for healthcare professionals and the general public. We access multiple resources for our Endocannabinoid System research.:

A popular resource is the National Center for Biotechnology Information. A sampling of abstracts of research involving the Endocannabinoid System and diseases is located to the right.

• The Endocannabinoid System and: EPILEPSY
• The Endocannabinoid System and: AUTISM
• The Endocannabinoid System and: HIV-1
• The Endocannabinoid System and: ALZHEIMER’S
• The Endocannabinoid System and: SCHIZOPHRENIA
• The Endocannabinoid System and: PARKINSON’S
• The Endocannabinoid System and: ALS
• The Endocannabinoid System and: MULTIPLE SCLEROSIS

Bottle photos, courtesy Wirtshafter Museum, Photo credit Kevin Manuel

The endocannabinoid system is a group of neuromodulatory lipids and their receptors in the brain that are involved in a variety of physiological processes including appetite, pain-sensation, mood, and memory; it mediates the psychoactive effects of cannabis and, broadly speaking, includes:

The endogenous arachidonate-based lipids, anandamide (N-arachidonoylethanolamide, AEA) and 2-arachidonoylglycerol (2-AG); these are known as “endocannabinoids” and are physiological ligands for the cannabinoid receptors.

The enzymes that synthesize and degrade the endocannabinoids, such as fatty acid amide hydrolase or monoacylglycerol lipase.

The cannabinoid receptors CB1 and CB2, two G protein-coupled receptors that are located in the central and peripheral nervous systems.

Endocannabinoids are all eicosanoids.

A recent study suggests less than 14% of medical schools say the words Endocannabinoid System. This is illogical for a biological system that has been discovered for decades. Study by David Allen, MD